Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

15

Revenue 2017

Neulasta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Neulasta was produced by Amgen.

FDA accepts Sandoz filing for biosimilar Neulasta

FDA accepts Sandoz filing for biosimilar Neulasta Neulasta (pegfilgrastim) is a long-acting granulocyte colony stimulating factor (G-CSF) that is used to bolster white cells in patients undergoing chemotherapy for cancer, and remains one of Amgen's ... The patents on Neulasta expired in the US in

Roche maintains top place in biologic sales

Roche maintains top place in biologic sales Novo Nordisk and Sanofi see large sales from their insulin products while Amgen's bone drug Prolia (denosumab) and chemotherapy side effects drug Neulasta(pegfilgrastim), make up the bulk of its

Amgen starts shipping Corlaner in US

Amgen starts shipping Corlaner in US Top seller Neulasta (pegfilgrastim) climbed 4% to $1.13bn, with the greatest growth coming from Prolia (denosumab) for osteoporosis - up 39% to $272m - and recently-introduced multiple myeloma therapy Kyprolis (carfilzomib) ... Launches this year already

Apotex latest to file Neupogen biosimilar in the US

Apotex latest to file Neupogen biosimilar in the US Meanwhile, biosimilar competition is also looming for Amgen's long-acting version of Neupogen, Neulasta(pegfilgrastim), which is due to lose US patent protection in October of this year.

Amgen banking on three launches in 2015

Amgen banking on three launches in 2015 Long-acting white blood cell stimulator Neulasta (pegfilgrastim) grew 7% to $1.1bn, although its short-acting predecessor Neupogen (filgrastim) slumped 11% thanks to competition from biosimilars. ... Bradway also highlighted the approval of a new on-body

[ Previous 5 results ] 1 2 3 4 5 6 7 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....